Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study

International Journal of Neuropsychopharmacology

Volumn 10, Issue 2, 2007, Pages 263-274

  Asakura, Satoshi ^a   Tajima, Osamu ^b   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

Fluvoxamine maleate; Generalized social anxiety disorder (GSAD); Liebowitz Social Anxiety Scale Japanese Version (LSAS J); Placebo controlled double blind study; Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

FLUVOXAMINE; PLACEBO;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISABILITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; JAPAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCLE STIFFNESS; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RETCHING; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM; SEROTONIN SYNDROME; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; STOMACH DISCOMFORT; THIRST; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; JAPAN; MALE; MIDDLE AGED; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 33847038810     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706006602     Document Type: Article

References (36)

1. Antony MM, Roth D, Swinson RP, Huta V, Devins GM (1998). Illness intrusiveness in individuals with panic disorder, obsessive-compulsive disorder, or social phobia. Journal of Nervous and Mental Disease 186, 311-315.
2. APA (1980). Diagnostic and Statistical Manual of Mental Disorders (3rd edn). Washington, D.C: American Psychiatric Association.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, D.C: American Psychiatric Association.
4. Asakura S, Inoue S, Sasaki F, Sasaki Y, Kitagawa N, Inoue T, Denda K, Ito M, Matsubara R, Koyama T (2002). Reliability and validity of the Japanese version of the Liebowitz Social Anxiety Scale. Seishin Igaku (Clinical Psychiatry) 44, 1077-1084.
5. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG (1998). Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry 59 (Suppl. 17), 54-60.
6. Chick J, Aschauer H, Hornik K (2004). Efficacy of fluvoxamine in preventing relapse in alchohol dependence: a one year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug and Alchohol Dependence 74, 61-70.
7. Clarvit SR, Schneier FR, Liebowitz MR (1996). The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. Journal of Clinical Psychiatry 57, 523-527.
8. Davidson JR (1998). Pharmacotherapy of social anxiety disorder. Journal of Clinical Psychiatry 59 (Suppl. 17), 47-53.
9. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH (1993). Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology 13, 423-428.
10. Davidson JR, Tobias JY, DuPont R, Stallings L, Barbato LM, van der Hoop RG, Li D (2004). Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 118-125.
11. Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U (1995). Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatrica Scandinavica 92, 351-358.
12. Furlan PM, DeMartinis N, Schweitzer E, Rickels K, Lucki I (2001). Abnomal salivarly cortisol levels in social phobic patients in response to acute psychological but physical stress. Biological Psychiatry 50, 254-259.
13. Greist JH (1995). The diagnosis of social phobia. Journal of Clinical Psychiatry 56 (Suppl. 5), 5-12.
14. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health.
15. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, 8-19.
16. Kirmayer LJ (1991). The place of culture in psychiatric nosology: Taijin kyofusho and DSM-III-R. Journal of Nervous and Mental Disease 179, 19-28.
17. Leon AC, Shear MK, Portera L, Klerman GL (1992). Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Social Psychiatry and Psychiatric Epidemiology 27, 78-82.
18. Liebowitz MR (1987). Social phobia. Modern Problems of Pharmacopsychiatry 22, 141-173.
19. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, Goetz D, Juster HR, Lin SH, Bruch MA, et al. (1999). Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression & Anxiety 10, 89-98.
20. Liebowitz MR, Nicholas A, Demartinis A, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM (2003). Efficacy of sertraline in severe generalized social anxiety disorder: results of an double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 785-792.
21. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, et al. (1992). Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Archives of General Psychiatry 49, 290-300.
22. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC (1996). Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Archives of General Psychiatry 53, 159-168.
23. Narrow WE, Rae DS, Robins LN, Regier DA (2002). Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Archives of General Psychiatry 59, 115-123.
24. Otsubo T, Akimoto Y, Yamada H, Koba R, Aoyama H, Tanaka K, Mimura M, Nakagome K, Kamijima K (2005). A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. Pharmacopsychiatry 38, 30-35.
25. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM (1992). Social phobia. Comorbidity and morbidity in an epidemiologic sample. Archives of General Psychiatry 49, 282-288.
26. Stein DJ, Le Roux L, Bouwer C, Van Heerden B (1998a). Is olfactory reference syndrome an obsessive-compulsive spectrum disorder? two cases and a discussion. Journal of Neuropsychiatry and Clinical Neuroscience 10, 96-99.
27. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. American Journal of Psychiatry 156, 756-760.
28. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998b). Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Journal of the American Medical Association 280, 708-713.
29. Suzuki Y, Sawamura K, Someya T (In Press). Polymorphisms in the 5-hygroxytryptamine 2A receptor and cytochromeP4502d6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology.
30. Takahashi T (1989). Social phobia syndrome in Japan. Comprehensive Psychiatry 30, 45-52.
31. Takahashi T, Ikeda K, Ishikawa M, Kitamura N, Tsukasaki T, Nakama D, Kameda T (2005). Interpersonal trust and social stress-induced cortisol elevation. Neuroendocrinology 16, 197-199.
32. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, et al. (2001). Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. American Journal of Psychiatry 158, 275-281.
33. van Vliet IM, den Boer JA, Westenberg HG (1994). Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berlin) 115, 128-134.
34. Watson D, Friend R (1969). Measurement of social-evaluative anxiety. Journal of Consulting and Clinical Psychology 33, 448-457.
35. Westenberg HGM, Stein DJ, Yang H, Li D, Barbato LM (2004). A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 24, 49-55.
36. Yamashita I (1993). Taijin-kyofu or Delusional Social Phobia. Sapporo, Japan: Hokkaido University Press.